ABSMC Pharmacy Policy Updates

Posted on Sep 5, 2018 in Uncategorized | 0 comments

Policy 2022: IV to PO Conversion Program

Overview: Approved at P&T and MEC, this policy allows Pharmacy to convert specific medications in eligible patients from current IV therapy to an oral bioequivalent regimen

MD Notification: A Pharmacy progress note will be entered for all IV to PO conversions

Eligible Patients: Patient is currently tolerating and taking other oral medications (No N/V) or is tolerating food or enteral feeds.

Ineligible Patients: ICU patients, any anatomical reason for impaired oral absorption of medications, treatment indication is outside of Pharmacy scope of practice for that specific medication. For antiinfectives, patients must have stable labs and a treatment indication within Pharmacy scope of practice

Medications (Medication specific nuances in attached policy)

Acetaminophen Famotidine Metronidazole
Azithromycin Fluconazole Multivitamins
Bactrim/Septra Folic Acid Pantoprazole
Ciprofloxacin Levofloxacin Potassium
Clindamycin Levothyroxine Thiamine
Doxycycline Linezolid Voriconazole

Pharmacy Audit Process: Staff will be independently reviewed by Pharmacy leadership to ensure the policy is being followed as outlined, and used only in those who met criteria

 

 

Questions/Feedback:  Please contact Pharmacy Management, Krista Bramble (BramblK@sutterhealth.org) or Jon Eggers (EggersJA@sutterhealth.org)

Krista Bramble Pharm.D.
Pharmacy Manager
Alta Bates Summit Medical Center – Summit Campus
510-869-8822 (ph)
510-206-6985(cell)

Jon Eggers, Pharm.D, BCPS
Clinical Coordinator
Summit Campus Pharmacy
Alta Bates Summit Medical Center
Phone| 510-869-1523
Fax| 510-869-6268

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *